for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S

NOVOB.CO

Latest Trade

680.10DKK

Change

2.70(+0.40%)

Volume

324,827

Today's Range

676.70

 - 

682.60

52 Week Range

406.90

 - 

684.50

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
677.40
Open
679.00
Volume
324,827
3M AVG Volume
41.18
Today's High
682.60
Today's Low
676.70
52 Week High
684.50
52 Week Low
406.90
Shares Out (MIL)
2,272.06
Market Cap (MIL)
1,200,735.00
Forward P/E
33.51
Dividend (Yield %)
1.38

Latest Developments

More

French company BIOCORP forms partnership with Novo Nordisk on 'smart pens' to help those with diabetes

Novo Nordisk To Pay $100 Mln In Settlement Agreement

Exscientia Files For U.S. IPO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry

Biotechnology & Drugs

Contact Info

Novo Alle 1

2880

Denmark

+45.44.448888

https://www.novonordisk.com/

Executive Leadership

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Jeppe Christiansen

Vice Chairman of the Board

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Maziar Mike Doustdar

Executive Vice President, International Operations

Key Stats

2.65 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2018

111.8K

2019

122.0K

2020

126.9K

2021(E)

137.5K
EPS (DKK)

2018

15.930

2019

16.380

2020

18.010

2021(E)

20.217
Price To Earnings (TTM)
35.42
Price To Sales (TTM)
9.24
Price To Book (MRQ)
23.48
Price To Cash Flow (TTM)
23.79
Total Debt To Equity (MRQ)
20.99
LT Debt To Equity (MRQ)
19.01
Return on Investment (TTM)
57.56
Return on Equity (TTM)
30.16

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up